Description
In This Episode:
- Kelly Norsworthy, MD, Deputy Division Director, Division of Hematologic Malignancies 1, Office of Oncologic Diseases, FDA Center for Drug Evaluation and Research
- Ashley Woods, MD, Hematologist, Division of Hematologic Malignancies 1, Office of Oncologic Diseases, FDA Center for Drug Evaluation and Research
- Susan Pandya, MD, Vice President, Clinical Development, Head of Cancer Metabolism Global Division, Servier Pharmaceuticals
- Stéphane de Botton, MD, PhD, Physician, Clinical Investigator, Head of Hematology, Gustave Roussy Cancer Center
- Amir Fathi, MD, Director of Leukemia Program, Massachusetts General Hospital
- Aura Ramos, RN, BSN, Research Nurse, Massachusetts General Hospital
- Matthew Newman, PharmD, Oncology Pharmacist, Johns Hopkins University
- Lucille Giunta, Patient and Clinical Trial Participant
Disclosure Statement
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed all their financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products or services used by or on patients. All of the relevant financial relationships for these individuals have been mitigated.
Faculty Disclosures
| Participant Name | Role | Financial Relationships | Type |
| Stephane de Botton | Speaker | Pfizer, AbbVie Inc., Servier Pharmaceuticals LLC, Bristol-Myers Squibb, Agios Pharmaceuticals, Inc., Astellas Pharma, forma therapeutics, Jazz Pharmaceuticals Inc., Celgene Corporation, syros pharmaceuticals | IC, IC, IC, IC, IC, IC, GC, IC, IC, IC |
| Amir Fathi | Speaker | Immunogen, Bristol-Myers Squibb, Genentech, Massachusets General Hospital, Celgene, Kite Pharma, Inc., Orum, Kura Oncology, AbbVie, Takeda Oncology, Forma, Menarini Group, Amgen, AbbVie, EnClear, Mablyitics, Pfizer, Novartis, Servier Pharmaceuticals LLC, PureTech, Remix, Autolus, Gilead Sciences Inc, Servier Pharmaceuticals LLC, Daiichi Sankyo Company, Bristol-Myers Squibb, Ipsen Biopharmaceuticals, Inc, Astellas Pharma, Rigel Pharmaceuticals, Inc. |
IC, IC, IC, E, IC, IC,
IC, IC, GC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, GC, IC,
GC, IC, IC, IC |
| Jennifer Gao | Program Committee | No Relationships | |
| Lucille Giunta | Speaker | No Relationships | |
| Matthew Newman | Speaker | No Relationships | |
| Kelly Norsworthy | Moderator | No Relationships | |
| Susan Pandya | Speaker | Servier Pharmaceuticals LLC, Servier Pharmaceuticals LLC | E, E |
| Aura Ramos | Speaker | No Relationships | |
| Ashley Woods | Speaker | No Relationships |
Planning Committee Disclosures
FDA staff involved in the development and review of this activity have disclosed no relevant financial relationships.
AACR staff involved in the development and review of this activity have disclosed no relevant financial relationships.
ONS staff involved in the development and review of this activity have disclosed no relevant financial relationships.
Accreditation Statement
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
Credit Designation Statement
AACR designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Oncology Nursing Society is accredited as a provider of nursing continuing professional development (NCPD) by the American Nurses Credentialing Center's Commission on Accreditation. Earn 1.50 contact hours of NCPD by watching the entire webinar recording, reading the accompanying product label, and completing an evaluation at myoutcomes.ons.org
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. A statement of credit will be issued only upon completion of the post-activity evaluation form and post-test which can be accessed via this page.
Claiming CME Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this enduring continuing medical education activity must complete the online CME Request for Credit Survey. Certificates will only be issued to those who complete the survey. The Request for Credit Survey is available here. Your CME certificate will be sent to you via email after the completion of the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 Medical Knowledge Maintenance of Certification (MOC) points in the American Board of Internal Medicine’s (ABIM) MOC program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS).
Questions on CME or CE
For CME: Please contact the Office of CME at (215) 440-9300 or cme@aacr.org.
For NCPD: Please contact ONS at 866-257-4667 or help@ons.org.
For CPE: Please contact HOPA at 877-467-2791 or education@hoparx.org.
CME: Request for Credit Survey
NCPD: To request Credit, click here.
CPE: To request Contact Hours, click here.